



# 51  
1623  
12210  
RECEIVED  
DEC 18 2000  
TECH CENTER 1600/2906

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: IMANISHI=2

In re Application of:	)	Art Unit: 1623
	)	
Takeshi IMANISHI et al.	)	Examiner: J. Crane
	)	
Appln. No.: 09/380,638	)	Washington, D.C.
	)	
Filed: September 7, 1999	)	December 7, 2000
	)	
For: NOVEL BICYCLONUCLEOSIDE	)	
AND OLIGONUCLEOTIDE	)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above- identified application, and any other application relying on the filing date of the above-identified application or cross- referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

(Check one of the boxes A-D)

[ ] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[ ] B. before the mailing date of a first office action on the merits.

12/08/2000 CVORACHA 00000044 09380638

01 FC:126

180.00 DP

☒ C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below).

*(Check one of the boxes "i" and "ii" below:)*

☒ i. Counsel certifies that, upon information and belief, each item of information listed herein was either

☒ (a) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in §1.56(c) more than three months prior to the filing of this IDS.

☒ ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in §1.17(p), presently believed to be \$240.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of the document listed is attached.

3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. Other information being provided for the examiner's consideration follows:


*A copy of the Supplementary European Report is attached.*

5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicants reserve the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicants

By:

  
Sheridan Neimark  
Reg. No. 20,520

624 Ninth Street, N.W., Su 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528  
SN:jaa  
F:\,Y\YUAS\imanishi2\pto\Ids.doc